Floatz logo

Capivasertib

Estrogen-Receptor Positive Breast Cancer

Imperial College LondonSmall moleculePhase 2Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
95/ 100

Competitive context

73 Active assets in the Estrogen-Receptor Positive Breast Cancer cohort.

Asset / SponsorPhaseRating
Exemestane
National Cancer Institute (NCI)
Phase 4BBB
Everolimus
UNC Lineberger Comprehensive Cancer Center
Phase 4BBB
Tamoxifen
Dana-Farber Cancer Institute
Phase 4BB
Abemaciclib
Jonsson Comprehensive Cancer Center
Phase 3BB
Palbociclib
Forward Pharmaceuticals Co., Ltd.
Phase 3BB

View all 50 →

Same molecule, other indications

Capivasertib is also rated in:

triple-negative breast carcinomaActive
BB
Indicative · Phase 3
71 / 100
View asset →
castration-resistant prostate carcinomaActive
BB
Indicative · Phase 3
66 / 100
View asset →
Her2-receptor negative breast cancerActive
BB
Indicative · Phase 3
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →